Harnessing the Anti-Tumor Mediators in Mast Cells as a New Strategy for Adoptive Cell Transfer for Cancer

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Fereydouni, Mohammad
    • Other Affiliation: University of North Carolina Greensboro
  • Motaghed, Mona
    • Other Affiliation: North Carolina A&T State University
  • Ahani, Elnaz
    • Other Affiliation: North Carolina A&T State University
  • Kafri, Tal
    • Affiliation: School of Medicine, Department of Microbiology and Immunology
  • Dellinger, Kristen
    • Other Affiliation: North Carolina A&T State University
  • Metcalfe, Dean D.
    • Other Affiliation: National Institutes of Health
  • Kepley, Christopher L.
    • Other Affiliation: Liberty University
Abstract
  • The emergence of cancer immunotherapies utilizing adoptive cell transfer (ACT) continues to be one of the most promising strategies for cancer treatment. Mast cells (MCs) which occur throughout vascularized tissues, are most commonly associated with Type I hypersensitivity, bind immunoglobin E (IgE) with high affinity, produce anti-cancer mediators such as tumor necrosis factor alpha (TNF-α) and granulocyte macrophage colony-stimulating factor (GM-CSF), and generally populate the tumor microenvironments. Yet, the role of MCs in cancer pathologies remains controversial with evidence for both anti-tumor and pro-tumor effects. Here, we review the studies examining the role of MCs in multiple forms of cancer, provide an alternative, MC-based hypothesis underlying the mechanism of therapeutic tumor IgE efficacy in clinical trials, and propose a novel strategy for using tumor-targeted, IgE-sensitized MCs as a platform for developing new cellular cancer immunotherapies. This autologous MC cancer immunotherapy could have several advantages over current cell-based cancer immunotherapies and provide new mechanistic strategies for cancer therapeutics alone or in combination with current approaches.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution 4.0 International
Journal title
  • Frontiers in Oncology
Journal volume
  • 12
Language
  • English
Version
  • Publisher
ISSN
  • 2234-943X

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details fonc-12-830199.pdf 2022-04-04 Public Download